Business Support · Founded 1993 · www.choksilab.in · BSE 526546 · · ISIN INE493D01013
No Notes Added Yet
Business
Choksi Laboratories Ltd. is primarily engaged in providing analytical testing services across various sectors. The company operates as a contract research and testing organization (CRTO), offering chemical, biological, and instrumental analysis of a wide range of products and materials. Their core services include quality control testing, regulatory compliance testing, environmental monitoring, and R&D support for industries such as pharmaceuticals, food and agro products, water, environmental samples, minerals, metals, and construction materials. The company makes money by charging fees for these specialized testing services, based on the type, complexity, and volume of analysis performed for its clients.
Revenue Mix
While specific revenue segmentation by industry is not always granularly disclosed, Choksi Laboratories' services can be broadly categorized by the sectors they serve:
Pharmaceutical & Healthcare Testing (Raw materials, finished products, stability studies, impurity profiling)
Food & Agricultural Product Testing (Nutritional analysis, contaminant testing, pesticide residues)
Environmental Testing (Water, wastewater, air, soil analysis)
Material Testing (Minerals, metals, construction materials)
These segments contribute based on the demand from respective industries for quality assurance and regulatory adherence.
Industry
Choksi Laboratories operates within the Testing, Inspection, and Certification (TIC) industry, which falls under the broader "Business Support" sector. The Indian TIC market is driven by increasing regulatory compliance, quality consciousness, and growth in manufacturing and exports. The industry is fragmented, with global majors (e.g., SGS, Bureau Veritas, Intertek) and numerous domestic players, ranging from large specialized labs to smaller regional ones. Choksi Laboratories is an established domestic player, particularly strong in Western India, known for its accreditations (like NABL) and range of analytical services, positioning itself as a reliable partner for industries seeking compliance and quality assurance.
MOAT
Accreditations & Certifications: Critical industry-specific accreditations (e.g., NABL - National Accreditation Board for Testing and Calibration Laboratories, ISO certifications, GLP) are significant barriers to entry, enhancing credibility and trust.
Specialized Expertise & Reputation: A long operating history and established reputation for reliable and accurate results build client trust and repeat business.
Capital-Intensive Infrastructure: Investing in advanced analytical equipment and infrastructure requires significant capital, which can deter new entrants.
Client Relationships: Established long-term relationships with industrial clients across diverse sectors.
Growth Drivers
Increasing Regulatory Scrutiny: Stricter quality and safety regulations from Indian and international bodies for food, pharmaceuticals, and environmental standards.
Growth in Manufacturing & Exports: Expanding manufacturing output and export activities in India necessitate more robust quality control and compliance testing.
Outsourcing Trend: Companies increasingly outsource analytical testing to specialized labs to gain objectivity, reduce in-house costs, and leverage expert capabilities.
Consumer Awareness: Growing consumer demand for high-quality, safe, and transparently tested products.
Healthcare & Pharmaceutical Sector Growth: India's booming pharmaceutical and healthcare industries drive consistent demand for drug testing and analysis.
Risks
Intense Competition: High competition from large multinational TIC players and a multitude of smaller, regional laboratories.
Technological Obsolescence & Capex: Continuous need for investment in new, advanced analytical equipment and technologies to remain competitive and meet evolving testing standards.
Regulatory Changes: Adverse changes in testing standards, accreditation requirements, or industry-specific regulations could impact operations and compliance costs.
Economic Downturn: Reduced industrial activity or slowdowns in key client sectors (e.g., pharma, food processing) can lead to decreased demand for testing services.
Manpower & Skill Shortage: Availability and retention of highly skilled scientific and technical personnel for complex analytical tasks.
Litigation Risk: Potential for legal liabilities arising from inaccuracies in testing results or data integrity issues.
Management & Ownership
Choksi Laboratories Ltd. is a promoter-led company, with the Choksi family playing a significant role in its management and ownership. The promoters typically hold a substantial stake, indicating aligned interests with the company's long-term performance. Management quality is generally seen as experienced within the analytical testing domain, having guided the company through its operational history and regulatory landscape. The ownership structure reflects a typical Indian family-controlled enterprise, with the public holding the remaining shares.
Outlook
Choksi Laboratories Ltd. operates in a sector with structural tailwinds driven by India's industrial growth, heightened regulatory focus on quality, and increasing outsourcing trends. The company's established accreditations and diverse service portfolio position it to benefit from these drivers, particularly in the pharmaceutical and food sectors. However, the outlook is balanced by intense competition from both domestic and international players, the necessity of continuous capital expenditure for technological upgrades, and the potential impact of economic fluctuations on industrial demand. Maintaining its reputation for reliability, expanding its service offerings, and navigating the evolving regulatory environment will be crucial for sustained growth and profitability.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 11 | 11 | 9 | 10 | 11 | 11 | 11 | 11 | 13 | 12 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 11 | 11 | 9 | 10 | 11 | 11 | 11 | 11 | 13 | 12 |
| Total Expenditure | 8 | 8 | 7 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| Operating Profit | 4 | 3 | 2 | 3 | 4 | 3 | 3 | 3 | 4 | 3 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Profit Before Tax | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Provision for Tax | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Profit After Tax | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Adjustments | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 |
| Profit After Adjustments | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Adjusted Earnings Per Share | 1 | 0.6 | 0.1 | 0.2 | 1.3 | 0.6 | 0.3 | 0.4 | 1.5 | 0.8 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 22 | 22 | 29 | 31 | 34 | 28 | 26 | 30 | 34 | 37 | 42 | 47 |
| Other Income | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 23 | 22 | 30 | 32 | 34 | 28 | 26 | 30 | 35 | 37 | 42 | 47 |
| Total Expenditure | 17 | 17 | 24 | 25 | 26 | 25 | 22 | 21 | 24 | 26 | 30 | 34 |
| Operating Profit | 6 | 5 | 6 | 7 | 8 | 3 | 5 | 9 | 10 | 10 | 11 | 13 |
| Interest | 2 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 | 3 | 3 | 4 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 5 | 5 | 6 | 6 | 8 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 | 2 | 0 | 0 | 1 |
| Profit Before Tax | 1 | 1 | 1 | 2 | 2 | -6 | -3 | 0 | 4 | 2 | 2 | 4 |
| Provision for Tax | 0 | 0 | 0 | 1 | 1 | -2 | -0 | 0 | 1 | 1 | 1 | 1 |
| Profit After Tax | 1 | 1 | 1 | 1 | 2 | -4 | -3 | 0 | 3 | 1 | 2 | 2 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 1 | 1 | 1 | 1 | 2 | -4 | -3 | 0 | 3 | 1 | 2 | 2 |
| Adjusted Earnings Per Share | 1.3 | 1 | 1.3 | 1.9 | 2.3 | -5.6 | -3.7 | 0.3 | 4.6 | 1.6 | 2.2 | 3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 14% | 12% | 8% | 7% |
| Operating Profit CAGR | 10% | 7% | 30% | 6% |
| PAT CAGR | 100% | 0% | 0% | 7% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 27% | 47% | 57% | 30% |
| ROE Average | 7% | 9% | 3% | 2% |
| ROCE Average | 9% | 11% | 8% | 7% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 19 | 20 | 21 | 22 | 24 | 20 | 18 | 18 | 21 | 22 | 24 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 6 | 8 | 4 | 6 | 14 | 27 | 29 | 28 | 24 | 18 | 15 |
| Other Non-Current Liabilities | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 2 | 3 | 2 |
| Total Current Liabilities | 12 | 14 | 14 | 16 | 13 | 14 | 16 | 16 | 13 | 19 | 24 |
| Total Liabilities | 38 | 43 | 41 | 45 | 55 | 64 | 65 | 63 | 59 | 62 | 65 |
| Fixed Assets | 19 | 18 | 20 | 26 | 35 | 33 | 50 | 47 | 45 | 43 | 48 |
| Other Non-Current Assets | 4 | 10 | 8 | 4 | 4 | 14 | 1 | 2 | 1 | 4 | 1 |
| Total Current Assets | 15 | 15 | 13 | 15 | 16 | 17 | 13 | 14 | 14 | 15 | 16 |
| Total Assets | 38 | 43 | 41 | 45 | 55 | 64 | 65 | 63 | 59 | 62 | 65 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Cash Flow from Operating Activities | 2 | 7 | 7 | 6 | 7 | 3 | 6 | 8 | 8 | 12 | 12 |
| Cash Flow from Investing Activities | -1 | -7 | -2 | -5 | -10 | -14 | -8 | -3 | -1 | -7 | -8 |
| Cash Flow from Financing Activities | -1 | 1 | -5 | -1 | 2 | 11 | 2 | -5 | -8 | -5 | -4 |
| Net Cash Inflow / Outflow | 0 | 0 | -0 | 0 | -1 | 0 | -0 | 0 | -0 | 0 | -0 |
| Closing Cash & Cash Equivalent | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 1.27 | 1.04 | 1.28 | 1.93 | 2.3 | -5.58 | -3.74 | 0.3 | 4.61 | 1.59 | 2.19 |
| CEPS(Rs) | 5.33 | 4.96 | 5.39 | 6.48 | 7.58 | 0.97 | 2.86 | 8.09 | 12.5 | 9.8 | 11.52 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 27.73 | 28.76 | 30.33 | 32.15 | 34.47 | 29.03 | 25.48 | 25.7 | 30.31 | 31.89 | 33.89 |
| Core EBITDA Margin(%) | 23.36 | 22.79 | 16.62 | 17.97 | 21.53 | 10.09 | 16.06 | 29.65 | 29.8 | 28 | 27.06 |
| EBIT Margin(%) | 13.41 | 10.61 | 9.66 | 10.01 | 11.36 | -13.58 | 0.04 | 11.98 | 21.02 | 12.88 | 11.67 |
| Pre Tax Margin(%) | 6.27 | 5.11 | 4.55 | 5.49 | 6.8 | -20.29 | -10.93 | 1.22 | 10.81 | 4.53 | 5.15 |
| PAT Margin (%) | 4.01 | 3.24 | 3.1 | 3.83 | 4.74 | -13.8 | -10.15 | 0.69 | 9.32 | 3.02 | 3.65 |
| Cash Profit Margin (%) | 16.89 | 15.49 | 13.06 | 12.81 | 15.64 | 2.41 | 7.77 | 18.76 | 25.28 | 18.59 | 19.2 |
| ROA(%) | 2.31 | 1.8 | 2.15 | 3.16 | 3.2 | -6.53 | -4.06 | 0.32 | 5.24 | 1.83 | 2.41 |
| ROE(%) | 4.45 | 3.67 | 4.34 | 6.19 | 6.9 | -17.57 | -13.74 | 1.16 | 16.46 | 5.12 | 6.65 |
| ROCE(%) | 9.39 | 7.32 | 8.41 | 10.49 | 10.14 | -8.27 | 0.02 | 6.75 | 13.9 | 9.18 | 9.45 |
| Receivable days | 129.38 | 139.36 | 110.28 | 96.82 | 100.96 | 102.27 | 107.63 | 112.09 | 110.99 | 104.68 | 94.63 |
| Inventory Days | 0 | 0 | 2.93 | 2.7 | 3.76 | 3.78 | 2.05 | 2.2 | 2.43 | 2.85 | 4.02 |
| Payable days | 6509.88 | 12405.93 | 541.1 | 549.74 | 591.84 | 763.82 | 800.65 | 813.96 | 479.72 | 408.62 | 551.15 |
| PER(x) | 5.98 | 10.61 | 13.31 | 13.39 | 6.11 | 0 | 0 | 85.46 | 7.26 | 26.6 | 54.94 |
| Price/Book(x) | 0.27 | 0.38 | 0.56 | 0.81 | 0.41 | 0.28 | 0.31 | 0.99 | 1.1 | 1.33 | 3.55 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.73 | 0.92 | 0.78 | 0.95 | 0.78 | 1.31 | 1.61 | 1.73 | 1.55 | 1.58 | 2.66 |
| EV/Core EBITDA(x) | 2.79 | 4 | 3.99 | 4.41 | 3.5 | 11.6 | 8.97 | 5.77 | 5.09 | 5.57 | 9.77 |
| Net Sales Growth(%) | 10.5 | 1.5 | 28.95 | 8.47 | 8.17 | -16.56 | -8.78 | 16.95 | 14.64 | 6.55 | 13.86 |
| EBIT Growth(%) | 4.54 | -19.68 | 17.4 | 26.84 | 8.76 | -199.78 | 100.27 | 35177.45 | 101.18 | -34.73 | 3.21 |
| PAT Growth(%) | -24.37 | -18.09 | 23.66 | 50.92 | 18.79 | -342.77 | 32.88 | 107.94 | 1450.72 | -65.43 | 37.26 |
| EPS Growth(%) | -24.37 | -18.09 | 23.65 | 50.93 | 18.8 | -342.76 | 32.88 | 107.94 | 1450.67 | -65.43 | 37.26 |
| Debt/Equity(x) | 0.6 | 0.68 | 0.53 | 0.55 | 0.7 | 1.56 | 2.04 | 1.94 | 1.44 | 1.32 | 1.19 |
| Current Ratio(x) | 1.23 | 1.08 | 0.91 | 0.96 | 1.21 | 1.14 | 0.8 | 0.9 | 1.11 | 0.77 | 0.68 |
| Quick Ratio(x) | 1.23 | 1.08 | 0.89 | 0.94 | 1.18 | 1.13 | 0.8 | 0.89 | 1.1 | 0.75 | 0.66 |
| Interest Cover(x) | 1.88 | 1.93 | 1.89 | 2.22 | 2.49 | -2.02 | 0 | 1.11 | 2.06 | 1.54 | 1.79 |
| Total Debt/Mcap(x) | 2.21 | 1.79 | 0.94 | 0.69 | 1.71 | 5.51 | 6.59 | 1.96 | 1.3 | 0.99 | 0.34 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 31.48 | 31.48 | 31.48 | 31.48 | 31.48 | 31.48 | 31.48 | 31.48 | 31.48 | 31.48 |
| FII | 0 | 0 | 0 | 1.94 | 4.31 | 5.69 | 5.69 | 6.03 | 7.02 | 10.01 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 68.52 | 68.52 | 68.52 | 66.58 | 64.21 | 62.83 | 62.83 | 62.49 | 61.5 | 58.51 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 |
| FII | 0 | 0 | 0 | 0.01 | 0.03 | 0.04 | 0.04 | 0.04 | 0.05 | 0.07 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.48 | 0.48 | 0.48 | 0.46 | 0.45 | 0.44 | 0.44 | 0.44 | 0.43 | 0.41 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +14% | +12% | +8% | +7% |
| Operating Profit CAGR | +10% | +7% | +30% | +6% |
| PAT CAGR | +100% | — | — | +7% |
| Share Price CAGR | +27% | +47% | +57% | +30% |
| ROE Average | +7% | +9% | +3% | +2% |
| ROCE Average | +9% | +11% | +8% | +7% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 31.48 | 31.48 | 31.48 | 31.48 | 31.48 | 31.48 | 31.48 | 31.48 | 31.48 | 31.48 |
| FII | 0 | 0 | 0 | 1.94 | 4.31 | 5.69 | 5.69 | 6.03 | 7.02 | 10.01 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 68.52 | 68.52 | 68.52 | 66.58 | 64.21 | 62.83 | 62.83 | 62.49 | 61.5 | 58.51 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 |
| FII | 0 | 0 | 0 | 0.01 | 0.03 | 0.04 | 0.04 | 0.04 | 0.05 | 0.07 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.48 | 0.48 | 0.48 | 0.46 | 0.45 | 0.44 | 0.44 | 0.44 | 0.43 | 0.41 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.